發(fā)布時間：2018-05-14 05:22

  本文選題：美羅培南 + 頭孢哌酮舒巴坦　； 參考：《中國藥房》2017年21期

【摘要】：目的:研究美羅培南(MPN)聯(lián)合頭孢哌酮舒巴坦(SCF)對3種多重耐藥(MDR)革蘭氏陰性桿菌的抗菌活性。方法:收集2016年1-12月泰山醫(yī)學院附屬醫(yī)院收治患者的痰、血、尿、腹水或引流液標本,從中分離得到的MDR-大腸埃希菌(EC)、MDR-肺炎克雷伯菌(KPN)、MDR-鮑曼不動桿菌(AB)各50株,采用瓊脂稀釋法、棋盤法測定MPN、SCF、MPN+SCF對MDR-EC、MDRKPN、MDR-AB的半數(shù)抑菌濃度(MIC_(50))、90%抑菌濃度(MIC_(90))及平均抑菌濃度(MIC_G),計算聯(lián)合抑菌濃度(FIC)指數(shù),采用K-B紙片法進行藥敏試驗。結(jié)果:MPN單用時MDR-EC、MDR-KPN、MDR-AB的MIC_G分別為36.82、82.45、34.32μg/mL,SCF單用時MDR-EC、MDR-KPN、MDR-AB的MIC_G分別為42.14、112.67、24.11μg/mL,MPN+SCF時MDR-EC、MDR-KPN、MDR-AB的MIC_G分別為25.97、56.64、11.36μg/mL,MDR-EC、MDR-KPN中的MIC_G為MPN+SCFMPNSCF,MDR-AB中的MIC_G為MPN+SCFSCFMPN,差異均有統(tǒng)計學意義(P0.05)。MPN+SCF對MDR-EC、MDR-KPN、MDR-AB的FIC最高分別為0~0.5(78.00%)、0~0.5(72.00%)、0.5~1.0(82.00%)。結(jié)論:MPN聯(lián)合SCF可有效提高對MDR-EC、MDR-KPN、MDR-AB等MDR革蘭氏陰性桿菌的抗菌活性,且兩藥聯(lián)用具有協(xié)同作用。
[Abstract]:Objective: to study the antibacterial activity of meropenem (MPN) combined with Cefoperazone sulbactam (SCF) against three multidrug resistant (MDR) gram-negative bacilli. Methods: samples of sputum, blood, urine, ascites or drainage fluid were collected from patients admitted to the affiliated Hospital of Taishan Medical College from January to December 2016. Fifty strains of MDR- Escherichia coli were isolated from the patients with MDR- MDR- Klebsiella pneumoniae (KPN)-Acinetobacter baumannii. Agar dilution method and chessboard method were used to determine the 50% inhibitory concentration of MDR-ECRKPNN SCF on MDR-ECRKPNN, MDR-AB) and the average inhibitory concentration of MPN SCF to MDR-ECRKPNN MDR-AB, and to calculate the index of combined inhibitory concentration (FICs). The drug sensitivity test was carried out by K-B disk method. 緇撴灉:MPN鍗曠敤鏃禡DR-EC,MDR-KPN,MDR-AB鐨凪IC_G鍒嗗埆涓，

本文編號：1886536